$334 Million is the total value of New Leaf Venture Partners, L.L.C.'s 20 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 5.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARVN | ARVINAS INC | $92,007,000 | -1.9% | 2,283,048 | 0.0% | 27.52% | +35.0% | |
| DCPH | DECIPHERA PHARMACEUTICALS INC | $85,910,000 | -33.9% | 2,086,723 | 0.0% | 25.70% | -8.9% | |
| PASG | New | PASSAGE BIO INC | $39,342,000 | – | 2,497,922 | +100.0% | 11.77% | – |
| HARP | HARPOON THERAPEUTICS INC | $33,830,000 | -21.7% | 2,921,405 | 0.0% | 10.12% | +7.8% | |
| PRNB | Sell | PRINCIPIA BIOPHARMA INC | $25,071,000 | -50.0% | 422,214 | -53.8% | 7.50% | -31.1% |
| ALEC | ALECTOR INC | $15,433,000 | +40.0% | 639,569 | 0.0% | 4.62% | +92.9% | |
| APTX | APTINYX INC | $7,107,000 | -36.8% | 3,290,079 | 0.0% | 2.13% | -13.0% | |
| ARAV | ARAVIVE INC | $5,451,000 | -57.9% | 946,423 | 0.0% | 1.63% | -42.0% | |
| AVRO | AVROBIO INC | $4,910,000 | -22.7% | 315,550 | 0.0% | 1.47% | +6.4% | |
| SRRA | Sell | SIERRA ONCOLOGY INC | $4,022,000 | -94.2% | 409,611 | -91.8% | 1.20% | -91.9% |
| ITRM | ITERUM THERAPEUTICS PLC | $3,947,000 | -39.8% | 1,456,303 | 0.0% | 1.18% | -17.1% | |
| XFOR | X4 PHARMACEUTICALS INC | $3,350,000 | -6.6% | 335,000 | 0.0% | 1.00% | +28.6% | |
| NERV | MINERVA NEUROSCIENCES INC | $2,706,000 | -15.3% | 449,500 | 0.0% | 0.81% | +16.6% | |
| CHMA | CHIASMA INC | $2,685,000 | -26.4% | 735,700 | 0.0% | 0.80% | +1.3% | |
| OBSV | OBSEVA SA | $2,170,000 | -36.9% | 900,501 | 0.0% | 0.65% | -13.1% | |
| CRNX | CRINETICS PHARMACEUTICALS INC | $2,073,000 | -41.4% | 141,000 | 0.0% | 0.62% | -19.4% | |
| CMRX | CHIMERIX INC | $1,944,000 | -29.1% | 1,350,000 | 0.0% | 0.58% | -2.2% | |
| STIM | Sell | NEURONETICS INC | $1,506,000 | -67.7% | 796,685 | -23.3% | 0.45% | -55.5% |
| UMRX | UNUM THERAPEUTICS INC | $742,000 | -42.6% | 1,795,545 | 0.0% | 0.22% | -21.0% | |
| PDSB | PDS BIOTECHNOLOGY CORP | $85,000 | -72.7% | 117,242 | 0.0% | 0.02% | -63.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DECIPHERA THERAPEUTICS INC | 25 | Q3 2023 | 44.4% |
| CHIMERIX INC | 25 | Q1 2023 | 20.9% |
| SIERRA ONCOLOGY INC | 22 | Q2 2022 | 14.9% |
| ARVINAS INC | 21 | Q3 2023 | 44.8% |
| CRINETICS PHARMACEUTICALS INC | 21 | Q3 2023 | 11.4% |
| OBSEVA SA | 20 | Q4 2021 | 8.5% |
| AVROBIO INC | 20 | Q1 2023 | 1.7% |
| HARPOON THERAPEUTICS INC | 19 | Q3 2023 | 20.0% |
| ALECTOR INC | 19 | Q3 2023 | 4.6% |
| ITERUM THERAPEUTICS PLC | 18 | Q3 2022 | 3.8% |
View New Leaf Venture Partners, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-06 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-09 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
View New Leaf Venture Partners, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.